louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06716060: Prevalence of Intestinal Parasitic Infections in Under-Five Children With Malnutrition in Sohag, Egypt
Official title: Prevalence of Intestinal Parasitic Infections in Under-Five Children With Malnutrition in Sohag, Egypt
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Malnutrition, Child
Lead sponsor: Sohag University
Sponsor class: OTHER
First posted: 2024-12-04
Enrollment: 100
Sex: ALL
Minimum age (years): 6
Maximum age (years): 5
Standard ages: CHILD
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: - 100 children aged between 6 months and 5 years, having malnutrition symptoms (growth retardation, failure to thrive, lethargy, generalized weakness, xerophthalmia, etc.)

Brief summary: This study aims to estimate the prevalence of intestinal parasitic infections in under-five children with malnutrition.

Detailed description: Malnourished children are vulnerable to IPIs suffering. In contrast, IPIs can contribute considerably to the evolution of undernutrition in the pediatric population, thus creating a potentially lethal cycle/vicious cycle of worsening illness and deteriorating nutritional status so, I will examine stool specimens of those children suffering from malnutrition.

One fecal sample will be collected from each patient in a labelled clean plastic container. Specimens will be immediately transferred to the Medical Parasitology Department laboratory The obtained fecal samples will be both macroscopically and microscopically examined. For microscopic examination, specimens will be examined by direct smear and FECT.

Anthropometric indices will be used for checking the nutritional status of the recruited children.

Eligibility criteria: Inclusion Criteria:

- 100 children aged between 6 months and 5 years, having malnutrition symptoms (growth retardation, failure to thrive, lethargy, generalized weakness, xerophthalmia, etc.) will be randomly recruited from pediatric outpatient clinics, Faculty of medicine, Sohag University.

Exclusion Criteria:

* children who took specific anthelmintic, antiprotozoal, purgatives or anti-diarrheal drugs three weeks before the stool sampling.

Primary outcomes:
measure: Prevalence of Intestinal Parasitic Infections in Under-Five Children with Malnutrition in Sohag, Egypt
timeFrame: 10 months
Secondary outcomes:
Other outcomes:
Locations:
city: Sohag
country: Egypt
facility: Esraa Ahmed Mahmoud Mohamed
state: Saqulta
Study officials:
References:
Clinical trial NCT00776360: The Effect of Oxytocin on the Gastric Emptying
Official title: The Effect of Oxytocin on Gastric Emptying in Patients With Gastro Paresis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: EARLY_PHASE1
Conditions: Postprocedural Delayed Gastric Emptying
Keywords: oxytocin
gastroparesis
diabetics
The effect of oxytocin on gastric emptying
Lead sponsor: Skane University Hospital
Sponsor class: OTHER
First posted: 2008-10-21
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The investigators are going to examine whether oxytocin has a prokinetic effect on gastric emptying in patients suffering from gastro paresis. Oxytocin infusion will be compared with sodium chloride infusion.

Detailed description: The investigators are going to examine whether oxytocin has a prokinetic effect on gastric emptying in patients suffering from gastro paresis. Oxytocin infusion will be compared with sodium chloride infusion.The gastric emptying is estimade by sitntigraphy during 70 minutes, and performed twicw. Once with saline and once with oxytocin.

Eligibility criteria: Inclusion Criteria:

* Gastroparesis in diabetics

Exclusion Criteria:

* Treatment with other prokinetics, other severe organic or psychological diseases

Primary outcomes:
measure: To examine whether oxytocin improves gastric emptying in gastroparesis
timeFrame: dec 2008-dec 22009
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03893760: Assessment of Right Ventricular Function in Advanced Heart Failure
Official title: Assessment of Right Ventricular Function in Advanced Heart Failure: Feasibility and Reliability of Right Ventricular Elastance
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Dilated Cardiomyopathy
Heart Failure
Keywords: heart Failure
ventricular elastance
dilated cardiomyopathy
right heart systolic function
right ventriculo-arterial coupling
Lead sponsor: ITAB - Institute for Advanced Biomedical Technologies
Sponsor class: OTHER
First posted: 2019-03-28
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Participants underwent the exams in the context of heart-transplant or advanced HF evaluation.

Brief summary: We examined the feasibility and reliability of a combined echocardiographic and right heart catheterization (RHC) approach for right ventriculo/arterial (R-V/A) coupling assessment in HF patients with dilated cardiomyopathy (D-CMP).

Detailed description: This is a single center, retrospective cross-sectional study. In 2016-17, for 6 months, we evaluated for eligibility 81 consecutive D-CMP patients afferent to "Niguarda Great Metropolitan Hospital" for RHC and echocardiography. All participants underwent the exams in the context of heart-transplant or advanced HF evaluation. Inclusion criteria were: 18 years old, given informed consent, D-CMP, New York Heart Association (NYHA) functional class II or III and reduced EF (≤ 35%). On the contrary, exclusion criteria were: missing the inclusion criteria and refused informed consent. The final sample consisted of 68 study participants (mean age 64±7 years, 82 % male).

Eligibility criteria: Inclusion Criteria:

* 18 years old
* Given informed consent
* D-CMP
* New York Heart Association (NYHA) functional class II or III
* Reduced EF (≤ 35%)

Exclusion Criteria:

* Missing the inclusion criteria
* Refused informed consent

Primary outcomes:
measure: Number of Participants with altered Right ventriculo/arterial (R-V/A) coupling over PAPm and Pulmonary Hypertension types
timeFrame: up to 24 weeks
Secondary outcomes:
measure: Rate of agreement in Right ventriculo/arterial (R-V/A) coupling assessment
timeFrame: up to 24 weeks
Other outcomes:
Locations:
city: Chieti
country: Italy
facility: University "G. d'Annunzio"
city: Milan
country: Italy
facility: Niguarda Great Metropolitan Hospital
Study officials:
affiliation: Institute of Cardiology - University "G. d'Annunzio" - Chieti, Italy
name: Francesco Bianco, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03477760: Multi-Drug Resistant Bacteria Carriage After Travel
Official title: Multi-Drug Resistant Bacteria Carriage After Travel: Comparison Between Patients Who Have Been Hospitalized in a Foreign Country, or Not During the Previous Year
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Beta Lactam Resistant Bacterial Infection (Disorder)
Lead sponsor: Hopital Lariboisière
Sponsor class: OTHER
First posted: 2018-03-26
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients admitted in one of the medical Dpt of our Hospital who have travelled in a foreign country during the previous year

Brief summary: During one month, from 1st to 30th November 2016, all patients admitted in one of the medical Dpt of our Hospital (Internal Medicine Dpt, Endocrinology, ICU) will be screened for multi-drug resistant bacteria carriage (after written consent). They will answer to a questionnaire about previous travel in a foreign country during the previous year, hospitalization or not during this travel.

Detailed description: During one month, from 1st to 30th November 2016, all patients admitted in one of the medical Dpt of our Hospital (Internal Medicine Dpt, Endocrinology, ICU) will be screened for multi-drug resistant bacteria carriage (after written consent), regardless a travel in a foreign country during the past year, or not. They will answer to a questionnaire about previous travel in a foreign country during the previous year, hospitalization or not during this travel. The aim of the study will be to compare the rate of carriage of multi-drug resistant bacteria among previous travelers, or not.

Eligibility criteria: Inclusion Criteria:

* All patients admitted in one of the medical Dpt of our Hospital who have travelled in a foreign country during the previous year

Exclusion Criteria:

* patients who were unable to give written consent

Primary outcomes:
measure: Multi-Drug Resistant bacteria carriage rate
timeFrame: At admission in our Hospital
Secondary outcomes:
Other outcomes:
Locations:
city: Paris
country: France
facility: URT, Hopital Lariboisiere
state: Ile-de-France
Study officials:
affiliation: Hopital Lariboisiere
name: Pierre O Sellier, M.D., Ph.D.
role: STUDY_DIRECTOR
References:
Clinical trial NCT01769560: MeFirst: A Tailored Intervention to HPV Vaccine Decision Making
Official title: MeFirst: A Tailored Intervention to HPV Vaccine Decision Making
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Human Papillomavirus-Related Carcinoma
Keywords: tailored intervention
college aged students
HPV
Lead sponsor: University of Michigan
Sponsor class: OTHER
First posted: 2013-01-16
Enrollment: 661
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 26
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: This study will test whether a tailored, online educational intervention increases HPV vaccine uptake and intent among female college students.

Detailed description: MeFirst is the first web-based, online, educational tool designed to promote Human Papillomavirus (HPV) vaccine awareness and understanding in an effort to improve HPV vaccine intent and uptake among female university students. HPV is the most common sexually transmitted infection and causes genital warts and cancer. The HPV vaccine has been recommended for girls ages 11-26 since 2006, yet vaccination rates remain low. Tailored online interventions may be more effective tools to promote behavior change among college students than traditional static interventions. The proposed study is a randomized controlled trial testing the efficacy of the MeFirst tool vs. standard static educational material on increasing HPV vaccination intent and uptake among female university students aged 18-26.

Eligibility criteria: Inclusion Criteria:

* enrolled at the University of Michigan

Exclusion Criteria:

* receipt of any doses of HPV vaccine

Primary outcomes:
measure: Determine the effect of the MeFirst tool, a tailored, online HPV vaccination decision-making guide, on HPV vaccination intention and/or uptake.
timeFrame: Immediately post intervention, 3 months and 12 months
Secondary outcomes:
measure: Determine the effect of the MeFirst tool on HPV-related knowledge.
timeFrame: Immediately post intervention, 3 months and 12 months
Other outcomes:
measure: Determine acceptability of the MeFirst tool to participants.
timeFrame: Immediately post intervention, 3 months and 12 months
Locations:
city: Ann Arbor
country: United States
facility: Univeristy of Michigan
state: Michigan
Study officials:
affiliation: University of Michigan
name: Vanessa K Dalton, MD, MPH
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03029260: Effects of Nervous System Mobilization
Official title: Effect of Nervous System Mobilization on Heat, Cold and Mechanical Pain Thresholds and Lower Limb Flexibility
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy Individuals
Lead sponsor: Aveiro University
Sponsor class: OTHER
First posted: 2017-01-24
Enrollment: 52
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: This study aims to compare the effect of tension neural mobilization versus sliding neural mobilization of the peroneal nerve on the heat and cold threshold, on pressure pain threshold and on flexibility both in the dominant lower limb (subjected to mobilization) and the non-dominant lower limb (not subjected to mobilization) in healthy young participants.

Detailed description: Sixty young and healthy participants will be randomly allocated to receive tension neural mobilization (n=30) or sliding neural mobilization (n=30). Data on heat threshold, cold threshold, pressure pain threshold and lower limb flexibility will be collected before the intervention, immediately after the intervention and at least 24h after the intervention.

Eligibility criteria: Inclusion Criteria:

* naïve to nervous system mobilization;

Exclusion Criteria:

* Any surgery or trauma in the previous 6 months; neurological, cardiorespiratory or rheumatic pathology; cancer.

Primary outcomes:
measure: Range of motion of the Straight Leg Raising test
timeFrame: Baseline
measure: Range of motion of the Straight Leg Raising test
timeFrame: Approximately 45 minutes after baseline measurements
measure: Range of motion of the Straight Leg Raising test
timeFrame: At least 24 hours after baseline measurements
Secondary outcomes:
measure: Heat threshold
timeFrame: Baseline
measure: Heat threshold
timeFrame: Approximately 45 minutes after baseline measurements
measure: Heat threshold
timeFrame: At least 24 hours after baseline measurements
measure: Cold threshold
timeFrame: Baseline
measure: Cold threshold
timeFrame: Approximately 45 minutes after baseline measurements
measure: Cold threshold
timeFrame: At least 24 hours after baseline measurements
measure: Pressure pain threshold
timeFrame: Baseline
measure: Pressure pain threshold
timeFrame: Approximately 45 minutes after baseline measurements
measure: Pressure pain threshold
timeFrame: At least 24 hours after baseline measurements
Other outcomes:
Locations:
city: Aveiro
country: Portugal
facility: School of Health Sciences
Study officials:
affiliation: University of aveiro
name: Anabela Silva, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01374360: Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry
Official title: Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Paroxysmal Nocturnal Hemoglobinuria
Keywords: PNH
Paroxysmal Nocturnal hemoglobinuria
Soliris
Eculizumab
Ravulizumab
Ultomiris
Lead sponsor: Alexion Pharmaceuticals, Inc.
Sponsor class: INDUSTRY
First posted: 2011-06-16
Enrollment: 6061
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: PNH Patients

Brief summary: This study is a collection of data to evaluate safety and characterize progression of Paroxysmal Nocturnal Hemoglobinuria (PNH).

Detailed description: Collection of data to evaluate safety and characterize progression of Paroxysmal Nocturnal Hemoglobinuria (PNH).

Eligibility criteria: Inclusion Criteria:

* Patients of any age, including minors, with a diagnosis of PNH or a detected PNH clone, including patients previously treated with Soliris or Ultomiris and withdrawn from treatment. Patients who are minors must have parent/legal guardian consent and must be willing and able to give assent, if applicable as determined by the Ethics Committees/Institutional Review Boards. Upon attaining adulthood, these patients must be re-consented.
* Ability to comprehend and sign consent to have data entered in the PNH Registry.

Exclusion Criteria:

* Inability or unwillingness to sign informed consent.
* Patients currently enrolled in an interventional clinical trial for treatment of PNH cannot be enrolled in the Registry at the same time.

Primary outcomes:
measure: Evaluate safety data specific to the use of Soliris and Ultomiris
timeFrame: Ongoing (up to 13 years)
Secondary outcomes:
measure: Collect data to characterize the progression of PNH as well as clinical outcomes, mortality and morbidity in Soliris or Ultomiris and non-Soliris or non- Ultomiris treated patients
timeFrame: Ongoing (up to 13 years)
Other outcomes:
Locations:
city: Boston
country: United States
facility: Contact the PNH Registry at Alexion Pharmaceuticals, Inc. for worldwide locations.
state: Massachusetts
Study officials:
affiliation: Alexion Pharmaceuticals, Inc.
name: Phillipe Gustovic
role: STUDY_DIRECTOR
References:
citation: Chou WC, Huang WH, Wang MC, Chang CS, Yeh SP, Chiou TJ, Chen YC, Lin TH, Shen MC; Taiwan PNH study group. Characteristics of Taiwanese patients of PNH in the international PNH registry. Thromb J. 2016 Oct 4;14(Suppl 1):39. doi: 10.1186/s12959-016-0094-0. eCollection 2016.
citation: Kelly RJ, Hochsmann B, Szer J, Kulasekararaj A, de Guibert S, Roth A, Weitz IC, Armstrong E, Risitano AM, Patriquin CJ, Terriou L, Muus P, Hill A, Turner MP, Schrezenmeier H, Peffault de Latour R. Eculizumab in Pregnant Patients with Paroxysmal Nocturnal Hemoglobinuria. N Engl J Med. 2015 Sep 10;373(11):1032-9. doi: 10.1056/NEJMoa1502950.
Clinical trial NCT05434260: Surgiphor vs Saline Joints
Official title: The Use of Povidone-iodine Sterile Solution to Reduce Periprosthetic Joint Infections: a Superiority Multicentre Randomized Trial
Study type: INTERVENTIONAL
Overall status: ENROLLING_BY_INVITATION
Phase: NA
Conditions: Prosthetic-joint Infection
Lead sponsor: Center for Innovation and Research Organization
Sponsor class: NETWORK
First posted: 2022-06-27
Enrollment: 868
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This study will be an open-label superiority, multicenter, single-blind, controlled randomized clinical trial investing the role of a PVP-I irrigation solution (Surgiphor) in reducing the risk of acute PJI in the 90 days following total hip and knee revision arthroplasty.


Eligibility criteria: Inclusion Criteria:

1. Patient ≥18 years old
2. Male or non-pregnant, non-lactating, postmenopausal or surgically sterilized females
3. Subjects scheduled to undergo total knee or total hip revision for aseptic reasons (per 2018 ICM criteria 5)
4. Subjects provide informed consent, which will consist of reading, signing, and dating the informed consent document after the Investigator, sub-Investigator or other designated study staff member has explained the study procedures, risks, and contact information. Subjects not willing to sign consent form to be randomized must be willing to sign alternate consent form to allow prospective data collection in the non-randomized arm of the study

Exclusion Criteria:

1. Subjects with known allergies to iodine or any other ingredients in Surgiphor
2. Subjects unwilling to sign informed consent
3. Subjects, for health reasons or other, in the opinion of the Investigator, with a life expectancy less than one year, which is the follow-up period of the study

Primary outcomes:
measure: Diagnosis of acute prosthetic joint infection
timeFrame: Within 90 days of revision surgery
Secondary outcomes:
measure: Wound complications
timeFrame: within 1 year of revision surgery
Other outcomes:
Locations:
city: Phoenix
country: United States
facility: University of Arizona
state: Arizona
city: Baltimore
country: United States
facility: Lifebridge Health
state: Maryland
city: Columbia
country: United States
facility: University of Missouri
state: Missouri
city: Philadelphia
country: United States
facility: Rothman Institute Orthopaedics
state: Pennsylvania
Study officials:
References:
Clinical trial NCT00918294: QuickOptTM Study - Using the QuickOptTM Method for Timing Cycle Optimization
Official title: QuickOptTM Study - Using the QuickOptTM Method for Timing Cycle Optimization
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Heart Failure
Keywords: CRT
heart failure
optimization
Timing cycle optimization methods
Lead sponsor: Abbott Medical Devices
Sponsor class: INDUSTRY
First posted: 2009-06-11
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: QuickOptTM optimization method provides a quicker, simpler and reliable alternative to standard echocardiography methods for optimization of sensed AV, paced AV and V-V delays in patients with CRT-P devices


Eligibility criteria: Inclusion Criteria:

* Patient meets current CRT-P indications and be implanted with an SJM CRT-P device with V-V timing and a compatible lead system
* Patient is able to provide written informed consent for study participation

Exclusion Criteria:

* Patient has limited intrinsic atrial activity (≤ 40 bpm)
* Patient has persistent or permanent AF
* Patient has a 2o or 3o heart block
* Patient is unable to provide analyzable echocardiogram images
* Patient's life expectancy is \<12 months
* Patient is \<18 years old
* Patient is pregnant
* Patient is on IV inotropic agents

Primary outcomes:
measure: To compare the aortic velocity time integral value derived by the QuickOptTM optimization method with that derived by the standard echocardiography optimization methods
timeFrame: 1 day
Secondary outcomes:
measure: Time required for each optimization method considered in this study
timeFrame: 1 day
measure: Effects of any spontaneous cardiac events during the QuickOpt optimization process and these events are not limited to premature ventricular complex (PVC), pacemaker-mediated tachycardia (PMT), atrial fibrillation (AF) and far-field R-wave oversensing
timeFrame: 1 day
Other outcomes:
Locations:
city: Beijing
country: China
facility: Fu Wai Hospital
Study officials:
References:
citation: Hua W, Wang DM, Cai L, Sun CF, Fu GS, Wang YT, Yan J, Luo ZL, Xu J, Wang ZY, Xu G, Shen FR, Xu W, Wang JF, Ren XJ, Jin W, Zhang N, Lau EO, Zhang S. A prospective study to evaluate the efficacy of an intracardiac electrogram-based atrioventricular and interventricular intervals optimization method in cardiac resynchronization therapy. Chin Med J (Engl). 2012 Feb;125(3):428-33.